Alphabiome is pioneering a new approach to decoding the microbiome and predicting drug response using advanced AI. Our platform delivers proprietary, IP-protected biomarkers backed by robust human data, ready for direct licensing.
Founded by MIT AI experts and Stanford Nobel Laureates in genetics, the company has already discovered over 100,000 novel biomarkers. The technology has been validated in large-scale animal trials and shown proof-of-concept in humans, with recent breakthroughs in predicting drug efficacy for Crohn’s and Colitis.

Alphabiome AI

Org chart

Teams

Offices